FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to a new crystalline form 1 of 2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide, to a based composition, the use of said crystalline form 1, methods for preparing it.
EFFECT: what is prepared is the new crystalline form 1 of 2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide effective for treating cancer.
10 cl, 9 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ABT-263 CRYSTALLINE FORMS AND SOLVATES FOR TREATMENT OF BCL-2 PROTEIN RELATED DISEASES | 2010 |
|
RU2551376C2 |
| SALTS AND CRYSTALLINE FORMS OF APOTTOSIS-INDUCING AGENT | 2011 |
|
RU2628560C2 |
| CRYSTALLINE BROMODOMAIN INHIBITORS | 2014 |
|
RU2675268C2 |
| SOLID FORMS OF GYRASE INHIBITOR (R)-1-ETHYL-3-[6-FLUORO-5-[2-(1-HYDROXY-1-METHYL-ETHYL) PYRIMIDIN-5-YL]-7-(TETRAHYDROFURAN-2-YL)-1H-BENZIMIDAZOL-2-YL] UREA | 2012 |
|
RU2625305C2 |
| COMBINATIONS FOR TREATING NASH/NAFLD AND ASSOCIATED DISEASES | 2019 |
|
RU2776369C1 |
| DIACYLGLYCEROL-ACYLTRANSFERASE 2 INHIBITORS | 2017 |
|
RU2719589C1 |
| LIQUID COMPOSITIONS (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)PYRROLIDINE-1-YL)PYRAZOLO[1,5-A]PYRIMIDINE-3-YL)-3-HYDROXYPYRROLIDINE-1-ARBOXAMIDE | 2017 |
|
RU2751767C2 |
| CRYSTAL FORMS OF TRIAZOLOPYRIMIDINE COMPOUND | 2017 |
|
RU2754856C2 |
| CRYSTALLINE FORMS OF [(S)-1-CARBAMOYL-2-(PHENYLPYRIMIDIN-2-YLAMINO)ETHYL]AMIDE 2-(2-METHYLAMINOPYRIMIDIN-4-YL)-1H-INDOLE-5-CARBONIC ACID | 2012 |
|
RU2631320C2 |
| CRYSTALLINE (2S,4R)-5-(5'-CHLOR-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOL-5-CARBOXAMIDO)-2-METHYLPENTANIC ACID AND ITS APPLICATIONS | 2017 |
|
RU2756223C2 |
